Translate Register Log In Login with facebookLogin and Register

Less use of musculoskeletal pain drugs if get vitamin D – Feb 2015

Impact of vitamin D supplementation on health-care use in a 25-hydroxyvitamin D-tested population in France: a population-based descriptive cohort study

Public Health Nutrition / Volume 18 / Issue 03 / February 2015, pp 554-561 Copyright © The Authors 2014 DOI:http://dx.doi.org/10.1017/S136898001400038X online: 31 March 2014

VitaminDWiki Summary of a study having lots of problems

Tested many (people for low vitamin D (aged 13-60, 84% were women) what criteria?
45 % of all tested filled a Vitamin D prescription
Having more than 6 prescriptions at the start of study

10 %No vitamin D prescription
16 %Vitamin D prescription

It appears that the people with low vitamin D levels were sicker

Before Vitamin DAfter
Muscle relaxant 13% 9%
Thyroid hormones 8% 10%


  • It is not clear how they decided whom to test for vitamin D
  • They prescribed both Vitamin D3 and Vitamin D2 - and did not seperate out the results
  • Does not mention how many people filled their prescription
  • Does not mention how many people actualy took the supplement
  • 24 of the 30 diseases which they excluded from this analysis are associated with low Vitamin D
  • A study like this can no longer be run in France:
    Vitamin D tests are no longer free in France as of 2015
  • They ignored those who had a Vitamin D prescription in the previous 5 months
%Total dose
(time period unknown)
24 % 200,000 IU
40 % 200,000 - 400,000 IU
36 % > 400,000 IU

See also VitaminDWiki

 Download the PDF from VitaminDWiki

Pascal Cailleta1a2a3 c1, Susan B Jaglala4, Laurent Laforesta2a5a6, Roland Chapurlata2a3a7, Muriel Rabillouda2a8a9, Michel Duchera10 and Anne-Marie Schotta1a2a3
a1 Hospices Civils de Lyon, Pôle Information Médicale Evaluation, Recherche, Clinical Epidemiology Group, Lyon, F-69003 France
a2 Lyon 1 University, Faculty of Medicine, Lyon, France
a3 INSERM, U1033, Physiopathology, Diagnosis and treatment of Bone Diseases, Epidemiological and Clinical approaches of Bone Diseasesʼ Group, Lyon, France
a4 University of Toronto, Department of Physical Therapy, Toronto, Ontario, Canada
a5 Hospices Civils de Lyon, Pharmacoepidemiology Unit, Lyon, France
a6 CNRS, UMR 5558, LBBE, Evaluation and Modeling with the Therapeutic Effects Group, Villeurbanne, France
a7 Hospices Civils de Lyon, Rheumatology, Lyon, France
a8 Hospices Civils de Lyon, Biostatistics Service, Lyon, France
a9 CNRS, UMR 5558, LBBE, Biostatistics – Health Group, Villeurbanne, France
a10 Hospices Civils de Lyon, Geriatric Hospital Group, Francheville, France

Objective Chronic vitamin D deficiency has been associated in some patients with diffuse musculoskeletal pain. These unspecific symptoms may partly explain why vitamin D deficiency is often diagnosed late.
Our aim was to analyse health-care claims after vitamin D supplementation in patients likely to have vitamin D deficiency.

Design Ambulatory health-care claims were compared before and after a vitamin D supplementation prescribed following a 25-hydroxyvitamin D assay.

Setting Health Insurance Fund (FHIF) database of the Rhône-Alpes area, France.

Subjects Among patients reimbursed for a 25-hydroxyvitamin D assay between 1 December 2008 and 31 January 2009, those supplemented with vitamin D after the assay were matched on the date of assay to patients who did not receive vitamin D.

Results Among the 3023 patients who had a 25-hydroxyvitamin D assay, 935 were consequently supplemented and matched to 935 patients not supplemented. Their median age was 50·0 and 49·5 years, respectively. Patients supplemented decreased their muscle relaxant consumption whereas no change was observed in the reference group, the difference between the two groups was significant (P=0·03). Second and third Pain Relief Ladder prescriptions decreased in both groups but not significantly differently between groups (P=0·58). There was a decrease in prescriptions of biological examination in both groups with no significant difference.

Conclusions Besides a decrease in muscle relaxant prescriptions in the supplemented group, it was difficult to assess the impact of vitamin D supplementation in patients likely to have vitamin D deficiency. Prospective cohort studies and randomized trials are needed to assess the efficiency of screening and supplementing vitamin D deficiency.
- - - - - - - - - -
It is well known from clinical studies that severe chronic vitamin D deficiency in adults causes osteomalacia, a bone condition characterized by bone pain, muscle weakness and fracture (either microfractures or transcortical fractures)(1). A number of articles have occasionally reported limited series of undiagnosed cases of osteomalacia in individuals with vitamin D deficiency due to either nutritional reasons (e.g. gastrointestinal disorder and/or bariatric surgery) or a total absence of sun exposure (e.g. veiled women)(2,3). When patients present with symptoms such as chronic bone pain, muscle weakness or fracture, osteomalacia is rarely suspected by the referring physician, and the lag between the development of symptoms and the vitamin D deficiency diagnosis may be long(4). It is possible that less severe but chronic vitamin D deficiency may cause comparable symptoms, although the 25-hydroxyvitamin D (25(OH)D) level at which symptoms may arise is not precisely known and probably highly variable across individuals®. Additionally, vitamin D deficiency has been found to be associated with increased incidence of fractures, falls, neuromuscular and endocrinal impairments, and chronic pain in elderly populations®®. However, very few studies have been conducted in healthy younger adults regarding the possible association between 25(OH)D levels and negative health outcomes although a significant proportion have vitamin D deficiency®8-®. These studies also found that the most deficient individuals had not been previously diagnosed. Other studies suggested that the delay in vitamin D deficiency diagnosis generates over-use of inappropriate health-care resources prior to the deficiency being diagnosed and treated(4,12-15). Based on these hypotheses, we could expect that in patients with no severe co-morbidities in a primary care setting, when vitamin D deficiency is diagnosed and treated by vitamin D supplementation, it is associated with a reduction in health-care use thereafter. The purpose of the present study was to analyse health-care use before and after a prescription of vitamin D supplementation following a 25(OH)D assay in a young to middle-aged population and to compare it with that in a non-supplemented group regarded as a reference group.

Experimental method

The French Health Insurance Funds
France has a publicly funded health system that systematically covers the population®6*. Briefly, maternity/ sickness and paternity insurance benefits are provided by the local Health Insurance Funds (Caisses Primaires d’Assurance Maladie) and 99-9 % of the French population is covered with a public insurance (i.e. 63 million individuals). Reimbursements relate to all medical procedures given to the patients: visits to health-care professionals, drugs, biological and medical procedures.

Drug reimbursement in the French Health Insurance Funds
France has still a pharmaceutical monopoly; most drugs are only available in pharmacies (community or hospital), with a mandatory medical prescription. Drugs containing high doses of vitamin D (e.g. 2500 pg (100 000IU) ampoules) must be prescribed before dispensation and are reimbursed on a 65 % regular basis.

Study design and study population
We conducted a before-after analysis of health-care use in a cohort of individuals who had a 25(OH)D assay and a vitamin D prescription after the assay and compared it with that in the reference group of individuals who did not have a vitamin D prescription after the assay. We used data from the Rhone-Alpes area (6 million inhabitants in 2009) provided by the ERASME database (Extraction, Recherches, Analyses pour un Suivi Medico-Economique)®7), a regional component of the French Health Insurance Funds (FHIF).
Patients aged 13-60 years who had a 25(OH)D assay between 1 December 2008 and 31 January 2009 were selected. Patients presenting with one of the thirty severe chronic diseases classified as ‘affection de longue duree’ (ALD)(18) were excluded, because people suffering severe chronic diseases are different from the general population regarding their health-care use.

The list of diseases giving access to the ALD programme is currently defined.

These chronic diseases include: VitaminDWiki comment
strokeVitamin D related
bone marrow failure and other chronic cytopenia
chronic arteriopathy with ischaemic manifestations
complicated bilharziasis
severe heart diseasesVitamin D related
chronic active liver disease and cirrhosisVitamin D related
primary or HIV acquired immunodeficiencyVitamin D related
type I or II diabetesVitamin D related
severe neuromuscular disease
(including myopathy and severe epilepsy)
Vitamin D related
severe and chronic haemo- globinopathy, haemophilia
severe arterial hypertensionVitamin D related
CHDVitamin D related
chronic respiratory failureVitamin D related
Alzheimer’s diseaseVitamin D related
Parkinson’s diseaseVitamin D related
metabolic inherited diseaseVitamin D related
cystic fibrosisVitamin D related
severe and chronic renal diseaseVitamin D related
paraplegia, vasculitides
systemic lupus erythematosusVitamin D related
sclerodermaVitamin D related
rheumatoid arthritisVitamin D related
long-term psychiatric diseaseVitamin D related
chronic ulcerative colitis and Crohn’s diseaseVitamin D related
multiple sclerosisVitamin D related
evolutive scoliosis
severe spondylarthritis
organ transplant consequencesVitamin D related
tuberculosisVitamin D related
leprosy and Vitamin D related
cancer diseasesVitamin D related.

This programme involves about 16 % of the patients insured by the FHIF. Patients with a vitamin D dispensation during the 5-month period preceding the assay, who died, or who were assigned to another healthcare insurance system during the follow-up period were also excluded.

Outcome and factors associated with vitamin D deficiency
Individuals were considered as vitamin D deficient if they had a record of 25(OH)D assay followed by vitamin D supplementation (i.e. at least one occurrence of ergo- calciferol (vitamin D2) or cholecalciferol (vitamin D3) reimbursement over the 3 months after the assay). They are referred to as the supplemented group. Patients who were not prescribed vitamin D after their assay were considered as not 25(OH)D deficient, and were regarded as the reference group. Each patient of the reference group was matched with a patient of the supplemented group on 25(OH)D assay date, within a range of 5 d. The index date for each pair was the date of supplementation for the supplemented patient. Health-care use for every patient was recorded over two 5-month periods. Five months was chosen for the following reasons. First, the French Insurance Healthcare database is subject to regular turnover; only 24 months’ data are stored, and each month, when the data of the newest month are entered in the system, those of the oldest month disappear. Second, we did not include in the analysis the period between the assay and the first prescription of vitamin D because no change in health-care use was expected during this period. Third, the last three months of the 24-month database is not as reliable as the preceding months because the data regarding prescriptions are entered in the system only at the time of the reimbursement. Although for most patients the reimbursement is done automatically when purchasing drugs with their health insurance card (carte ‘VITAL’) from the pharmacy, a minority (those who do not have their card when purchasing the drugs) do not appear in the database until they send their claims by mail. For comparing health-care use between pre- and post-supplementation periods, we extracted the following information from the database: age, sex, number of physician visits and recorded medical interventions (according to the French classification of medical procedures), different drug prescriptions, drug classes (defined by Anatomical Therapeutical Chemical (ATC) codes(19)) per distinct dates of prescription, medical imaging examinations, incident sick leaves and hospitalizations. The medical procedures were also classified as therapeutic or diagnostic. We identified and extracted reimbursements for specific drugs or biological examinations that were expected to be prescribed in patients presenting with vitamin D deficiency symptoms, such as diffuse musculoskeletal pain, asthenia or apparent depression. Regarding drugs, we considered analgesics of the second and third rung of the WHO’s Pain Relief Ladder (PRL)(20,21), muscle relaxants, corticosteroids, thyroid hormones, iron-based preparations and antidepressants. Analgesics corresponding to the first rung of the PRL were not considered as they are too highly prone to over-the-counter use, and consequently estimation of their use would be strongly biased. Antiepileptic drugs were abstracted as they may be responsible for a vitamin D deficiency. We analysed claims for the following biological examinations: cell blood counts, transaminase level, serum creatinine and thyroid-stimulating hormone level, since they are expected to be prescribed in the case of vitamin D deficiency symptoms such as unspecific musculoskeletal pain.

Statistical analysis
The study population was described using means and standard deviations for continuous variables and frequencies and proportions for discrete variables. The supplemented and the reference groups were compared using the t test when variables were continuous and the j2 test when variables were discrete. Health-care use within each group was compared before and after the index date using a paired t test on the same sample for continuous variables, McNemar’s j2 test for binomial discrete variables and Bowker’s test for discrete variables with more than two categories. A P value of 0-05 or less was considered statistically significant. Analyses were performed using the SAS Enterprise Guide version 4-3.

Characteristics of the supplemented group
Over the two-month inclusion period (1 December 2008-31 January 2009), 3023 patients aged 13-60 years were identified (Fig. 1). Their mean age was 47-5 (sd 11-0) years, their median age was 49-8 years and 84-1 % were women. The first assay recorded was a 25(OH)D3 assay in almost all cases (98-5 %). Among these patients, 45-2 % (n 1367) received vitamin D supplementation following the assay and 935 of them were matched to the 935 controls who did not receive any 25(OH)D during the whole follow-up period. The mean age of the supplemented population was 46-9 (sd 10-8) years, their median age was 50-0 years and 85-1 % were women. Baseline characteristics are shown in Table 1. Half of the patients were 50-60 years old, 26-1 % were 40-50 years old and 23-9% were 13-40 years old. Most patients (66-4%) had up to two different classes of drugs prescribed over the 5-month baseline period before the 25(OH)D assay and 9-5 % had at least one sick leave. Thirteen per cent of patients were prescribed muscle relaxants, 15-7 % corticosteroids, and 23-2 % a second or third PRL analgesic.

Characteristics of the reference group
Baseline characteristics of the reference group are shown Table 1. The supplemented group had higher baseline health-care use compared with the reference group as seen by the number of distinct pharmacy prescriptions (15-9 % with six or more prescriptions v. 9-7 %, P < 0-001), different ATC drug classes reimbursed (33-6 % with more than two classes per prescription v. 27-7 %, P = 0-01) and most of the study drugs (P < 0-05 for antidepressants, corticosteroids, muscle relaxants and analgesics).

Before and after comparisons
In the supplemented group, 24 % of the patients received less than 5000 pg (200 000IU) over the 5-month follow-up, approximately 40 % of the patients received between 5000 and 10 000 pg (200 000 and 400 000 IU) and 36 % received more than 10000 pg (400 000 IU). Prescriptions of drugs expected to be associated with vitamin D deficiency symptoms are shown in Table 2. In the supplemented group, fewer patients were treated by muscle relaxants after supplementation than before (13-1% v. 8-6%, P < 0-001). Such a pattern was not observed in the reference group, where there was no change in muscle relaxant prescription frequency (10-1 % v. 10-7 %, P = 0-68). Regarding second and third PRL analgesics, prescriptions tended to decrease in both groups although this did not reach statistical significance in the supplemented group (23-2% v. 21-2%, P=0-19 in supplemented group; 19-2% v. 16-0%, P = 0-04 in reference group). There was no change in the number of specialists visited during the post-supplementation period compared with the pre-supplementation period in both groups.

Fig. 1 Flowchart of the study (ERASME, Extraction, Recherches, Analyses pour un Suivi Medico-Economique (database); ALD, ‘affection de longue duree’; 25(OH)D, 25-hydroxyvitamin D)

The overall number of pharmacy prescriptions per patient did not change significantly; neither did the number of sick leaves or medical imaging examinations per patient. The mean number of diagnosis-related procedures per patient did not change significantly. Between-group comparisons are displayed in Table 3. In the supplemented group, a higher proportion of patients decreased their use of muscle relaxants than in the reference group (10-2 % v. 7-3%, P = 0-03) and a lower proportion of patients decreased their use of thyroid hormones (0-5% v. 1-6%, P=0-03). Regarding the supplemented group, we searched for whether there was a switch from muscle relaxants towards antidepressants, but we did not observe any statistically significant relationship between decrease in use of muscle relaxants and increase in use of antidepressants. For biological tests expected to be prescribed to patients with vitamin D deficiency symptoms, the supplemented group and reference group had similar decreasing patterns.


In this population-based cohort of patients who had a 25- (OH)D assay during winter, we targeted a young to middle- aged population aged 13-60 years who was free of heavy chronic disease and assessed global health-care use as well as specific prescriptions expected to be associated with vitamin D deficiency symptoms. We observed a moderate but statistically significant decrease in some prescriptions potentially associated with vitamin D deficiency symptoms i.e. pain and asthenia, particularly in muscle relaxant prescriptions. We also observed a decrease in prescriptions of second and third PRL analgesics but this was similar to the reference group. Besides, prescription of vitamin D supplementation in patients likely to have a vitamin D deficiency was not associated with a global decrease in the other health-care consumptions as measured by the number of physician visits or the number of diagnostic or therapeutic procedures performed.
It has been described in the literature that many patients with vitamin D deficiency may suffer from unspecific chronic fatigue or musculoskeletal pain and that the mean delay from symptoms to diagnosis of vitamin D deficiency is long(4,12-15). In a before-after study conducted in Switzerland in 2005 among female asylum seekers with chronic complaints for bone pain, proximal muscular weakness, a change in gait and/or fatigue, the authors found a mean duration of symptoms of 2-5 years before a diagnosis of vitamin D deficiency was established. The mean number of emergency medical visits decreased by 44 % in the sample after the diagnosis of vitamin D deficiency and vitamin D supplementation was established.
Table Baseline characteristics/Health-care use
25(OH)D, 25-hydroxyvitamin D; ERASME, Extraction, Recherches, Analyses pour un Suivi Medico-Economique; FHIF, French Health Insurance Funds; PRL, WHO's Pain Relief Ladder.
'Anatomical Therapeutic Chemical classification of drugs.

Similarly, the mean number of analgesic drugs prescribed decreased by 51 % after deficiency was treated(4). In a previous study conducted by our university department of general practice in the Rhone-Alpes area in a cohort of 196 women with no chronic disease aged from 19 to 49 years, who wore concealing clothing and who consulted their general practitioner from January through March 2008, it was found that 95-9% of women had a 25(OH)D level < 75nmol/l and 53-6 % a level <30 nmol/l. Of all women studied, 53 % had asthenia and 45 % had musculoskeletal pain(3). That study was consistent with other European studies showing that all these patients with unspecific musculoskeletal pain had not been screened for 25(OH)D, and that 30-59 months had elapsed before the deficiency was diagnosed(3,22).

In the present study we observed a significant decrease in muscle relaxant prescriptions in patients who had a 25- (OH)D assay followed by vitamin D supplementation in the 3 months. This decrease was significant whereas no decrease was observed in the reference group. Unfortunately, we could not assess the consumption of frequently used painkillers, as most of them are delivered over the counter. That is why we had to consider only the second and third PRL analgesics. A decrease in second and third PRL analgesic prescriptions was observed in both groups and thus could not be associated with the correction of vitamin D deficiency. However, chronic pain associated with longterm vitamin D deficiency might not often require second and third PRL analgesic prescriptions but mostly first PRL analgesics.

We observed an increase in the use of thyroid hormones and antidepressants after vitamin D supplementation. This result could be explained by the fact that vitamin D deficiency investigation could be triggered by unspecific clinical signs like asthenia, which could be also due to hypothyroidism and depression. Therefore, an increase in use of pharmacotherapies indicated in hypothyroidism or depression after a 25(OH)D supplementation could signal a concomitant diagnosis of these diseases, associated with or caused by a vitamin D deficiency(23,24).

Presence of reimbursement for a given patient

25(OH)D, 25-hydroxyvitamin D; ERASME, Extraction, Recherches, Analyses pour un Suivi Medico-Economique; FHIF, French Health Insurance Funds; PRL, WHO's Pain Relief Ladder.

We did not observe an overall decrease in health-care use after 25(OH)D supplementation in patients likely to have a vitamin D deficiency. The total number of physician visits and therapeutic and diagnostic-related procedures did not decrease. There are several possible explanations for these observations. The main limitation of our study is the lack of information regarding 25(OH)D results in our administrative database. We assumed that patients who received supplementation after a 25(OH)D assay were deficient and that those who did not were not. However, we have no information on the degree of vitamin D deficiency and it is possible that some physicians may have overprescribed vitamin D. Nevertheless, if vitamin D was prescribed in non-deficient individuals no beneficial effect on health-care use may be expected in those patients. We assumed that clinicians who prescribed 25(OH)D assays, prescribed consequently vitamin D in case of vitamin D deficiency. However, it is possible that some patients have not complied with these prescriptions. Additionally, we cannot assess the appropriateness of the dose of vitamin D prescribed and some patients may not have received sufficient doses. Another explanation for our results is the limited time frame of the study. It is possible that 5 months was not enough to observe a significant effect of the supplementation, especially if the dose was inadequate. A final explanation would be that vitamin D supplementation has a limited effect on healthcare use(25). We observed a significant decrease in muscle relaxant use and non-significant decrease in analgesic use subsequent to vitamin D supplementation, which was not associated with an increase of antidepressant use indicated in some cases of persistent neuropathic pain. There is emerging evidence on the efficacy of vitamin D to improve asthenia and/or pain in 25(OH)D-deficient patients(26) but the efficacy of vitamin D in pain relief is still debated. A Cochrane review from 2010 stated that the existing randomized controlled trials were too small to reach meaningful conclusions regarding the hypothesis of vitamin D supplementation as a treatment for chronic pain(27).


Our findings only partially support our initial hypothesis that vitamin D supplementation of individuals with vitamin D deficiency decreases health-care use. We observed a decrease in myorelaxing drug claims only in the supplemented group v. the reference group, with no significant switch towards other musculoskeletal pain pharmacotherapies.
TableBefore-after evolution
No overall decrease in diagnostic or therapeutic medical procedures was observed. Our study highlights potential areas for future research, including the frequency of undiagnosed vitamin D deficiency associated with diffuse musculoskeletal pain in the general population and the investigation of the efficacy of vitamin D supplementation on these symptoms in randomized controlled clinical trials.


  1. Cianferotti L & Marcocci C (2012) Subclinical vitamin D deficiency. Best Pract Res Clin Endocrinol Metab 26, 523-537.
  2. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. (2012) Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 97, 1153-1158.
  3. Le Goaziou MF, Contardo G, Dupraz C et al. (2011) Risk factors for vitamin D deficiency in women aged 20-50 years consulting in general practice: a cross-sectional study. Eur J Gen Pract 17, 146-152.
  4. de Torrente de la Jara G, Pecoud A & Favrat B (2006) Female asylum seekers with musculoskeletal pain: the importance of diagnosis and treatment of hypovitaminosis D. BMC Fam Pract 23, 4.
  5. Annweiler C, Allali G, Allain P et al. (2009) Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 16, 1083-1089.
  6. Annweiler C, Schott AM, Berrut G et al. (2009) Vitamin D-related changes in physical performance: a systematic review. J Nutr Health Aging 13, 893-898.
  7. Christakos S & Deluca HF (2011) Minireview: Vitamin D: is there a role in extraskeletal health? Endocrinology 152, 2930-2936.
  8. Tangpricha V, Pearce EN, Chen TC et al. (2002) Vitamin D insufficiency among free-living healthy young adults. Am J Med 112, 659-662.
  9. Chapuy MC, Preziosi P, Maamer M et al. (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7, 439-443.
  10. Daly RM, Gagnon C, Lu ZX et al. (2012) Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population- based study. Clin Endocrinol (Oxf) 77, 26-35.
  11. Forrest KYZ & Stuhldreher WL (2011) Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 31, 48-54.
  12. Nellen JF, Smulders YM, Jos Frissen PH et al. (1996) Hypovitaminosis D in immigrant women: slow to be diagnosed. BMJ 312, 570-572.
  13. Al-Said Y, Al-Rached H, Al-Qahtani H et al. (2009) Severe proximal myopathy with remarkable recovery after vitamin D treatment. Can J Neurol Sci 36, 336-339.
  14. Lyman D (2005) Undiagnosed vitamin D deficiency in the hospitalized patient. Am Fam Physician 71, 299-304.
  15. Fabbriciani G, Pirro M, Leli C et al. (2010) Diffuse muscoskeletal pain and proximal myopathy: do not forget hypovitaminosis D. J Clin Rheumatol 16, 34-37.
  16. Caisse Nationale d’Assurance Maladie des Travailleurs Salaries (2013) Getting informed about health insurance. http://www.ameli.fr/l-assurance-maladie/connaitre-l-assurance- maladie/getting-informed-about-health-insurance/ (accessed January 2014).
  17. Fender P & Weill A (2004) Epidemiology, public health and medical rates databases. Rev Epidemiol Sante Publique 52, 113-117.
  18. Nolte E, Knai C, McKee M, on behalf of World Health Organization (2008) Managing chronic conditions. Experience in eight countries. http://www.euro.who.int/data/assets/pdf_file/0008/98414/E92058.pdf (accessed January 2014).
  19. World Health Organization (2013) Guidelines for ATC classification and DDD assignment. http://www.whocc.no/ atc_ddd_publications/guidelines/ (accessed January 2014).
  20. World Health Organization (2014) WHO’s cancer pain ladder for adults. http://www.who.int/cancer/palliative/ painladder/en/ (accessed January 2014).
  21. Vargas-Schaffer G (2010) Is the WHO analgesic ladder still valid? Can Fam Physician 56, 514-517.
  22. McBeth J, Pye SR, O’Neill TW et al. (2010) Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. Ann Rheum Dis 69, 1448-1452.
  23. Mozaffari-Khosravi H, Nabizade L, Yassini-Ardakani SM et al. (2013) The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: a randomized clinical trial. J Clin Psychopharmacol 33, 378-385.
  24. Bozkurt NC, Karbek B, Ucan B et al. (2013) The association between severity of vitamin D deficiency and Hashimoto’s thyroiditis. Endocr Pract 19, 479-484.
  25. Warner AE & Arnspiger SA (2008) Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. J Clin Rheumatol 14, 12-16.
  26. Daniel D & Pirotta MV (2011) Fibromyalgia - should we be testing and treating for vitamin D deficiency? Aust Fam Physician 40, 712-716.
  27. Straube S, Derry S, Moore RA et al. (2010) Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev issue 1, CD007771.

Attached files

ID Name Comment Uploaded Size Downloads
7371 Impact of vitamin D supplementation on health-care use.pdf PDF admin 20 Nov, 2016 16:49 274.42 Kb 280
See any problem with this page? Report it (FINALLY WORKS)